194 results
P
patients with cancers
I/C
F-NLR scoring system, high F-NLR score vs. low F-NLR score
O
overall survival (OS) and disease-free survival (DFS)/progression-free survival (PFS)
P
bladder cancer (BC) patients
I/C
18 F-FDG PET/CT, clinical response and nonresponse
O
tumor response to neoadjuvant chemotherapy
P
thyroid cancer (TCa) patients
I/C
F-18 fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT), ultrasonography (US)
O
detection of cervical lymph node (LN) metastasis
P
patients with vertebral compression fractures
I/C
F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), differentiation of benign and malignant vertebral compression fractures
O
diagnostic performance, sensitivity, specificity, positive likelihood ratio, negative likelihood ratio
P
gynecological cancer
I/C
18 F-FDG PET, management of patients with recurrent gynecological cancers
O
changes in management
P
Asian people living with HIV
I/C
switching to bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF), staying on baseline regimens
O
maintained 100% virological suppression at week 48 with no treatment-emergent drug resistance and safety profiles comparable to those seen in people who stayed on baseline regimens
P
BPH patients with DU
I/C
transurethral surgical treatment, pharmacological treatment
O
improvements in Q
P
children
I/C
calcium phosphate (CaP) derivatives, no-intervention/placebo or Fluoride (F) use alone
O
caries preventive and tooth-remineralizing effect
P
low-income, food-insecure
I/C
Food is Medicine interventions, control
O
fruit and vegetable intake, glycated hemoglobin (A1C) levels